The big picture:
Tellurium Dioxide powder enriched with the stable Te-130 isotope is essential for producing Iodine-131, a radiopharmaceutical widely utilized in imaging and treating hyperthyroidism and thyroid cancer. The final step in this production process involves irradiating the stable Te-130 isotope at the Tehran reactor, resulting in the generation of Iodine-131.
Key points:
- Introduction of this product marks a pivotal moment for Iran, enabling domestic production of Iodine-131.
- Sustainable production capabilities for Iodine-131 have now been established within Iran.
- Ability to produce Tellurium Dioxide powder with varying levels of Te-130 enrichment and final product specifications has been achieved.
- The development significantly reduces Iran's vulnerability to external supply chain threats.
Go deeper:
Tellurium Dioxide powder enriched with stable isotope Te-130 is among the most widely utilized stable isotope products globally, playing a crucial role in creating diagnostic and therapeutic radiopharmaceuticals. By manufacturing this product domestically, Iran not only addresses its internal healthcare needs but also opens avenues for exporting to international markets, thereby generating foreign exchange revenue.
303/204
